Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.47 |
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247786 | 0.95 | SPHK2 (0.47) | SPHK2SPHK1LTA4HHRH3 | |
| SCHEMBL7247863 | 0.90 | LTA4H (0.48) | SPHK2SPHK1LTA4HSMN1; SMN2 | |
| SCHEMBL7249762 | 0.84 | KDM4E (0.46) | SPHK2SPHK1LTA4HHRH3 | |
| SCHEMBL7244329 | 0.82 | SIGMAR1 (0.47) | SPHK2SPHK1HRH3 | |
| SCHEMBL7244055 | 0.80 | LTA4H (0.50) | LTA4HHRH3 | |
| SCHEMBL7251610 | 0.80 | LTA4H (0.50) | LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL7508739 | 0.79 | LTA4H (0.49) | LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL7246199 | 0.79 | LTA4H (0.49) | LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL7243161 | 0.79 | LTA4H (0.49) | LTA4HHRH3 | |
| SCHEMBL7400679 | 0.78 | LTA4H (0.41) | SPHK2SPHK1LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534525-B1 | Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, | WARNER-LAMBERT & COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6124317-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |